Oskar Hansson
Position: Group leaders
Phone: +47 21 07 76 49
Email:
 

Publications 2017

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K, Swedish BioFINDER study (2017)
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Neurology, 88 (10), 930-937
PubMed 28179466

Idland AV, Wyller TB, Støen R, Eri LM, Frihagen F, Ræder J, Chaudhry FA, Hansson O, Zetterberg H, Blennow K, Bogdanovic N, Brækhus A, Watne LO (2017)
Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium
J Alzheimers Dis, 55 (1), 371-379
PubMed 27662296

Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O, Geneva Task Force for the Roadmap of Alzheimer's Biomarkers (2017)
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Neurobiol Aging, 52, 196-213
PubMed 28317649

Publications 2016

Andersson CH, Hansson O, Minthon L, Andreasen N, Blennow K, Zetterberg H, Skoog I, Wallin A, Nilsson S, Kettunen P (2016)
A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease
J Alzheimers Dis, 53 (4), 1353-63
PubMed 27392867

Frisoni GB, Hansson O (2016)
Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?
Lancet Neurol, 15 (7), 650-1
PubMed 27302222

Habchi J, Chia S, Limbocker R, Mannini B, Ahn M, Perni M, Hansson O, Arosio P, Kumita JR, Challa PK, Cohen SI, Linse S, Dobson CM, Knowles TP, Vendruscolo M (2016)
Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease
Proc Natl Acad Sci U S A, 114 (2), E200-E208
PubMed 28011763

Hagell P, Westergren A, Janelidze S, Hansson O (2016)
The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls
Qual Life Res, 25 (10), 2571-7
PubMed 27198749

Hahn A, Schain M, Erlandsson M, Sjölin P, James GM, Strandberg OT, Hägerström D, Lanzenberger R, Jögi J, Olsson TG, Smith R, Hansson O (2016)
Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology
J Nucl Med (in press)
PubMed 27765859

Hall S, Surova Y, Öhrfelt A, Swedish BioFINDER Study, Blennow K, Zetterberg H, Hansson O (2016)
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
Mov Disord, 31 (6), 898-905
PubMed 26878815

Hansson O, Egeland T, Gill P (2016)
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Int J Legal Med, 131 (2), 303-317
PubMed 27807625

Hansson O, Gouras G (2016)
Brain activity and Alzheimer's disease: a complex relationship
Brain, 139 (Pt 8), 2109-10
PubMed 27457228

Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN (2016)
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease
Alzheimers Res Ther, 8 (1), 17
PubMed 27121148

Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N, Alzheimer's Disease Neuroimaging Initiative (2016)
Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment
Neurobiol Aging, 48, 172-181
PubMed 27710807

Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N (2016)
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
Alzheimers Dement (Amst), 4, 76-84
PubMed 27722193

Janelidze S, Hertze J, Nägga K, Nilsson K, Nilsson C, Swedish BioFINDER Study Group, Wennström M, van Westen D, Blennow K, Zetterberg H, Hansson O (2016)
Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
Neurobiol Aging, 51, 104-112
PubMed 28061383

Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, Blennow K, Hansson O (2016)
Plasma β-amyloid in Alzheimer's disease and vascular disease
Sci Rep, 6, 26801
PubMed 27241045

Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, van Westen D, Stomrud E, Minthon L, Blennow K, Swedish BioFINDER study group, Hansson O (2016)
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Ann Clin Transl Neurol, 3 (3), 154-65
PubMed 27042676

Lattanzi S, Silvestrini M, Verbeek MM, Mollenhauer B, Lindqvist D, Janelidze S, Hansson O (2016)
Increased CSF biomarkers of angiogenesis in Parkinson disease
Neurology, 86 (18), 1747-8
PubMed 27164652

Lindholm B, Nilsson MH, Hansson O, Hagell P (2016)
External validation of a 3-step falls prediction model in mild Parkinson's disease
J Neurol, 263 (12), 2462-2469
PubMed 27646115

Lindqvist D, Prokopenko I, Londos E, Middleton L, Hansson O (2016)
Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism
J Parkinsons Dis, 6 (1), 99-108
PubMed 26756745

Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O, Alzheimer's Disease Neuroimaging Initiative (2016)
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
EMBO Mol Med, 8 (10), 1184-1196
PubMed 27534871

Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O (2016)
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
Nat Commun, 7, 10918
PubMed 26948379

Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K, ADNI Investigators (2016)
Plasma tau in Alzheimer disease
Neurology, 87 (17), 1827-1835
PubMed 27694257

Palmqvist S, Mattsson N, Hansson O (2016)
Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
Brain (in press)
PubMed 27383527

Palmqvist S, Mattsson N, Hansson O, Alzheimer’s Disease Neuroimaging Initiative (2016)
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Brain, 139 (Pt 4), 1226-36
PubMed 26936941

Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K (2016)
Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio - a cross-validation study against amyloid PET
J Neurochem, 139 (4), 651-658
PubMed 27579672

Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Koziorowski D, Aasly JO, Lynch T, Mellick GD, Mohan M, Silburn PA, Sanotsky Y, Vilariño-Güell C et al. (2016)
Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism
Brain, 140 (Pt 1), 98-117
PubMed 27807026

Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, Englund E, Hansson O (2016)
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Brain, 139 (Pt 9), 2372-9
PubMed 27357347

Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hägerström D, Jögi J, Borroni E, Schöll M, Honer M, Hansson O (2016)
Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy
Mov Disord, 32 (1), 108-114
PubMed 27709757

Smith R, Schöll M, Honer M, Nilsson CF, Englund E, Hansson O (2016)
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
Acta Neuropathol, 133 (1), 149-151
PubMed 27900460

Smith R, Wibom M, Olsson T, Hägerström D, Jögi J, Rabinovici GD, Hansson O (2016)
Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation
J Alzheimers Dis, 51 (2), 339-43
PubMed 26836192

Surova Y, Lampinen B, Nilsson M, Lätt J, Hall S, Widner H, Swedish BioFINDER study, van Westen D, Hansson O (2016)
Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease
PLoS One, 11 (6), e0157755
PubMed 27362763

van Westen D, Lindqvist D, Blennow K, Minthon L, Nägga K, Stomrud E, Zetterberg H, Hansson O (2016)
Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET
Sci Rep, 6, 20709
PubMed 26856756

Vanderstichele HM, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V, Mauroo K, Brix B, Hansson O (2016)
Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes
J Alzheimers Dis, 53 (3), 1121-32
PubMed 27258423

Voevodskaya O, Sundgren PC, Strandberg O, Zetterberg H, Minthon L, Blennow K, Wahlund LO, Westman E, Hansson O, Swedish BioFINDER study group (2016)
Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
Neurology, 86 (19), 1754-61
PubMed 27164711

Öhrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H, Bouaziz-Amar E, Hugon J, Paquet C, Blennow K (2016)
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease
Alzheimers Res Ther, 8 (1), 41
PubMed 27716408

Publications 2015

Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H (2015)
Amyloid biomarkers in Alzheimer's disease
Trends Pharmacol Sci, 36 (5), 297-309
PubMed 25840462

Gallo V, Brayne C, Forsgren L, Barker RA, Petersson J, Hansson O, Lindqvist D, Ruffmann C, Ishihara L, Luben R, Arriola L, Bergareche A, Gavrila D, Erro ME, Vanacore N, Sacerdote C, Bueno-de-Mesquita B, Vermeulen R, Seelen M, Sieri S, Masala G, Ramat S, Kyrozis A, Thricopolou A, Panico S et al. (2015)
Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study
Neurodegener Dis, 15 (6), 331-8
PubMed 26375921

Gill P, Haned H, Bleka O, Hansson O, Dørum G, Egeland T (2015)
Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches-Twenty years of research and development
Forensic Sci Int Genet, 18, 100-17
PubMed 25866376

Gouras GK, Olsson TT, Hansson O (2015)
β-Amyloid peptides and amyloid plaques in Alzheimer's disease
Neurotherapeutics, 12 (1), 3-11
PubMed 25371168

Gustavsson AM, Stomrud E, Abul-Kasim K, Minthon L, Nilsson PM, Hansson O, Nägga K (2015)
Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness
Cerebrovasc Dis Extra, 5 (2), 41-51
PubMed 26120319

Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O (2015)
Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease
Ann Clin Transl Neurol, 3 (1), 12-20
PubMed 26783546

Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, Cenci MA, Hansson O (2015)
Increased CSF biomarkers of angiogenesis in Parkinson disease
Neurology, 85 (21), 1834-42
PubMed 26511451

Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P (2015)
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls
Alzheimers Res Ther, 7 (1), 40
PubMed 26136856

Lindholm B, Hagell P, Hansson O, Nilsson MH (2015)
Prediction of falls and/or near falls in people with mild Parkinson's disease
PLoS One, 10 (1), e0117018
PubMed 25635687

Nilsson M, Szczepankiewicz F, van Westen D, Hansson O (2015)
Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson's Disease Dementia
PLoS One, 10 (11), e0141825
PubMed 26528541

Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Alzheimer's Disease Neuroimaging Initiative, Minthon L, Blennow K, Olsson M, Hansson O, Swedish BioFINDER Study Group (2015)
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Neurology, 85 (14), 1240-9
PubMed 26354982

Ramezani A, Nägga K, Hansson O, Lönn J, Sjöwall J, Katoozian F, Mansouri S, Nayeri F (2015)
Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis
Fluids Barriers CNS, 12, 22
PubMed 26408034

Silajdžić E, Björkqvist M, Hansson O (2015)
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease
BMC Neurol, 15, 8
PubMed 25651913

Stomrud E, Minthon L, Zetterberg H, Blennow K, Hansson O (2015)
Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
Alzheimers Dement (Amst), 1 (4), 403-11
PubMed 27239521

Surova Y, Nilsson M, Lätt J, Lampinen B, Lindberg O, Hall S, Widner H, Nilsson C, van Westen D, Hansson O (2015)
Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy
Neuroradiology, 57 (11), 1079-91
PubMed 26253801

Tangen GG, Engedal K, Bergland A, Moger TA, Hansson O, Mengshoel AM (2015)
Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease
Int Psychogeriatr, 27 (8), 1401-9
PubMed 25644091

Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB et al. (2015)
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Brain, 138 (Pt 9), 2701-15
PubMed 26220940

Wennström M, Hall S, Nägga K, Londos E, Minthon L, Hansson O (2015)
Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
Alzheimers Res Ther, 7 (1), 63
PubMed 26434635

Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM (2015)
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies
PLoS One, 10 (8), e0135458
PubMed 26270969

Publications 2014

Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L, Hansson O, Wallin A, Zetterberg H, Blennow K, Öhrfelt A (2014)
SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease
Mol Neurodegener, 9, 53
PubMed 25418885

Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, Skoog I, Lambert JC, Au R, Launer L, Wolf PA, Younkin S, Seshadri S (2014)
Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study
Alzheimers Dement, 11 (3), 249-57.e1
PubMed 25217292

Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D, Blankenstein MA, Scheltens P, van der Flier WM (2014)
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?
Alzheimers Dement, 10 (6), 713-723.e2
PubMed 24721526

Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O (2014)
CSF biomarkers and clinical progression of Parkinson disease
Neurology, 84 (1), 57-63
PubMed 25411441

Hansson O, Gill P, Egeland T (2014)
STR-validator: an open source platform for validation and process control
Forensic Sci Int Genet, 13, 154-66
PubMed 25178680

Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM (2014)
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease
Alzheimers Res Ther, 6 (3), 25
PubMed 24987465

Hertze J, Nägga K, Minthon L, Hansson O (2014)
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study
BMC Neurol, 14, 64
PubMed 24685003

Hölttä M, Minthon L, Hansson O, Holmén-Larsson J, Pike I, Ward M, Kuhn K, Rüetschi U, Zetterberg H, Blennow K, Gobom J (2014)
An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease
J Proteome Res, 14 (2), 654-63
PubMed 25490617

Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K (2014)
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Alzheimers Dement, 11 (10), 1180-90
PubMed 25533203

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative (2014)
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease
JAMA Psychiatry, 71 (10), 1183-91
PubMed 25162367

Lindholm B, Hagell P, Hansson O, Nilsson MH (2014)
Factors associated with fear of falling in people with Parkinson's disease
BMC Neurol, 14, 19
PubMed 24456482

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM (2014)
Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls
Acta Neuropathol, 127 (5), 633-43
PubMed 24633805

Martínez-Morillo E, Nielsen HM, Batruch I, Drabovich AP, Begcevic I, Lopez MF, Minthon L, Bu G, Mattsson N, Portelius E, Hansson O, Diamandis EP (2014)
Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms
J Proteome Res, 13 (2), 1077-87
PubMed 24392642

Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennström M (2014)
Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies
J Alzheimers Dis, 40 (2), 343-50
PubMed 24448788

Nägga K, Hansson O, van Westen D, Minthon L, Wennström M (2014)
Increased levels of hyaluronic acid in cerebrospinal fluid in patients with vascular dementia
J Alzheimers Dis, 42 (4), 1435-41
PubMed 25024336

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O (2014)
Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography
JAMA Neurol, 71 (10), 1282-9
PubMed 25155658

Silajdžić E, Constantinescu R, Holmberg B, Björkqvist M, Hansson O (2014)
Flt3 ligand does not differentiate between Parkinsonian disorders
Mov Disord, 29 (10), 1319-22
PubMed 25044107

Publications 2013

Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, Mercken M, Andreasson U, Parent S, Lipari F, Ohrfelt A, Bjerke M, Minthon L, Zetterberg H, Blennow K, Nutu M (2013)
Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease
Brain Res, 1513, 117-26
PubMed 23541617

Gallo V, Wark PA, Jenab M, Pearce N, Brayne C, Vermeulen R, Andersen PM, Hallmans G, Kyrozis A, Vanacore N, Vahdaninia M, Grote V, Kaaks R, Mattiello A, Bueno-de-Mesquita HB, Peeters PH, Travis RC, Petersson J, Hansson O, Arriola L, Jimenez-Martin JM, Tjønneland A, Halkjær J, Agnoli C, Sacerdote C et al. (2013)
Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort
Neurology, 80 (9), 829-38
PubMed 23390184

Hertze J, Palmqvist S, Minthon L, Hansson O (2013)
Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease
Dement Geriatr Cogn Dis Extra, 3 (1), 113-22
PubMed 23687506

Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K (2013)
Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease
PLoS One, 8 (6), e66381
PubMed 23799095

Johansson P, Almqvist EG, Johansson JO, Mattsson N, Andreasson U, Hansson O, Wallin A, Blennow K, Zetterberg H, Svensson J (2013)
Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease
PLoS One, 8 (11), e81989
PubMed 24312390

Johansson P, Åberg D, Johansson JO, Mattsson N, Hansson O, Ahrén B, Isgaard J, Åberg ND, Blennow K, Zetterberg H, Wallin A, Svensson J (2013)
Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease
Psychoneuroendocrinology, 38 (9), 1729-37
PubMed 23473966

Kaufman E, Hall S, Surova Y, Widner H, Hansson O, Lindqvist D (2013)
Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy
PLoS One, 8 (4), e62354
PubMed 23626805

Leoni V, Solomon A, Lövgren-Sandblom A, Minthon L, Blennow K, Hansson O, Wahlund LO, Kivipelto M, Björkhem I (2013)
Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: candidate marker of brain health
J Alzheimers Dis, 36 (4), 739-47
PubMed 23666171

Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O (2013)
Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment
Brain Behav Immun, 33, 183-9
PubMed 23911592

Nielsen HM, Ek D, Avdic U, Orbjörn C, Hansson O, Netherlands Brain Bank, Veerhuis R, Rozemuller AJ, Brun A, Minthon L, Wennström M (2013)
NG2 cells, a new trail for Alzheimer's disease mechanisms?
Acta Neuropathol Commun, 1, 7
PubMed 24252600

Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K, Hansson O, Ohrfelt A (2013)
Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders
Dement Geriatr Cogn Disord, 36 (1-2), 99-110
PubMed 23860354

Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Blennow K, Hansson O (2013)
Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia
J Alzheimers Dis, 33 (1), 45-53
PubMed 22890100

Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O (2013)
Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia
J Alzheimers Dis, 34 (3), 673-9
PubMed 23254629

Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Höjrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J (2013)
A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls
J Alzheimers Dis, 33 (4), 1021-32
PubMed 23076076

Rosén C, Hansson O, Blennow K, Zetterberg H (2013)
Fluid biomarkers in Alzheimer's disease - current concepts
Mol Neurodegener, 8, 20
PubMed 23800368

Surova Y, Szczepankiewicz F, Lätt J, Nilsson M, Eriksson B, Leemans A, Hansson O, van Westen D, Nilsson C (2013)
Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography
PLoS One, 8 (6), e66022
PubMed 23785466

Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM (2013)
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy
PLoS One, 8 (1), e53250
PubMed 23308173

Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O (2013)
Plasma tau levels in Alzheimer's disease
Alzheimers Res Ther, 5 (2), 9
PubMed 23551972

Publications 2012

Björkqvist M, Ohlsson M, Minthon L, Hansson O (2012)
Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease
PLoS One, 7 (1), e29868
PubMed 22279551

Brunnström H, Hansson O, Zetterberg H, Londos E, Englund E (2012)
Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies
Int J Geriatr Psychiatry, 28 (7), 738-44
PubMed 22911491

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012)
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
Arch Gen Psychiatry, 69 (1), 98-106
PubMed 22213792

Daborg J, Andreasson U, Pekna M, Lautner R, Hanse E, Minthon L, Blennow K, Hansson O, Zetterberg H (2012)
Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease
J Neural Transm (Vienna), 119 (7), 789-97
PubMed 22488444

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O (2012)
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
Arch Neurol, 69 (11), 1445-52
PubMed 22925882

Hansson O, Stomrud E, Vanmechelen E, Östling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I (2012)
Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study
J Alzheimers Dis, 28 (1), 231-8
PubMed 21955816

Janelidze S, Ventorp F, Erhardt S, Hansson O, Minthon L, Flax J, Samuelsson M, Traskman-Bendz L, Brundin L (2012)
Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters
Psychoneuroendocrinology, 38 (6), 853-62
PubMed 23062672

Johansson P, Almqvist EG, Johansson JO, Mattsson N, Hansson O, Wallin A, Blennow K, Zetterberg H, Svensson J (2012)
Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease
Psychoneuroendocrinology, 38 (7), 1058-66
PubMed 23159010

Kruczyk M, Zetterberg H, Hansson O, Rolstad S, Minthon L, Wallin A, Blennow K, Komorowski J, Andersson MG (2012)
Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment
J Neural Transm (Vienna), 119 (7), 821-31
PubMed 22573144

Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012)
Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum
PLoS One, 7 (10), e47387
PubMed 23082161

Nutu M, Bourgeois P, Zetterberg H, Portelius E, Andreasson U, Parent S, Lipari F, Hall S, Constantinescu R, Hansson O, Blennow K (2012)
Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases
Neuromolecular Med, 15 (1), 169-79
PubMed 23225274

Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O (2012)
Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study
PLoS One, 7 (6), e38639
PubMed 22761691

Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H (2012)
Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease
J Alzheimers Dis, 29 (1), 171-6
PubMed 22214781

Silajdžić E, Minthon L, Björkqvist M, Hansson O (2012)
No diagnostic value of plasma clusterin in Alzheimer's disease
PLoS One, 7 (11), e50237
PubMed 23209684

Stomrud E, Forsberg A, Hägerström D, Ryding E, Blennow K, Zetterberg H, Minthon L, Hansson O, Londos E (2012)
CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly
Dement Geriatr Cogn Disord, 33 (2-3), 156-63
PubMed 22722670

Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, Hansson O, Miles AK, Janciauskiene SM, Warden D, Smith AD, Wilcock G, Kalsheker N, Rees R, Matharoo-Ball B, Morgan K (2012)
Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid
J Alzheimers Dis, 28 (3), 625-36
PubMed 22045497

Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O (2012)
CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease
PLoS One, 7 (1), e30525
PubMed 22303443

Publications 2011

Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H, Alzheimer's Disease Neuroimaging Initiative (2011)
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease
Neurobiol Aging, 33 (8), 1599-608
PubMed 21684041

Johansson P, Johansson JO, Labrie F, Mattsson N, Hansson O, Blennow K, Zetterberg H, Wallin A, Ohlsson C, Svensson J (2011)
Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women
Clin Endocrinol (Oxf), 75 (3), 301-8
PubMed 21521348

Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J (2011)
Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population
J Alzheimers Dis, 24 (3), 537-46
PubMed 21297262

Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Månsson JE, Johansson JO, Olsson B, Wallin A, Svensson J, Blennow K, Zetterberg H (2011)
Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility
Neuromolecular Med, 13 (2), 151-9
PubMed 21567187

Movérare-Skrtic S, Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Zetterberg H, Blennow K, Svensson J (2011)
Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study
Exp Gerontol, 47 (2), 179-82
PubMed 22210159

Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, Blennow K, Zetterberg H, Aarsland D (2011)
Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
Int J Alzheimers Dis, 2011, 495025
PubMed 21966597

Rosén C, Mattsson N, Johansson PM, Andreasson U, Wallin A, Hansson O, Johansson JO, Lamont J, Svensson J, Blennow K, Zetterberg H (2011)
Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases
Front Aging Neurosci, 3, 1
PubMed 21442044

Schneider P, Buerger K, Teipel S, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Rujescu D, Moeller HJ, Zetterberg H, Blennow K, Ernst A, Bergmann A, Hampel H (2011)
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment
Biol Psychiatry, 70 (2), 145-51
PubMed 21457948

Stubendorff K, Hansson O, Minthon L, Londos E (2011)
Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease--measured from a fixed cognitive level
Dement Geriatr Cogn Disord, 32 (6), 408-16
PubMed 22327504

Publications 2010

Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller HJ, Teipel SJ, Ernst A, Bergmann A, Hampel H (2010)
Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment
J Clin Psychiatry, 72 (4), 556-63
PubMed 21208578

De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2010)
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people
Arch Neurol, 67 (8), 949-56
PubMed 20697045

Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, Zetterberg H, Blennow K, Fedynyshyn JP, Allauzen S (2010)
Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease
PLoS One, 5 (12), e15725
PubMed 21209907

Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010)
Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years
J Alzheimers Dis, 21 (4), 1119-28
PubMed 21504133

Mattsson N, Johansson P, Hansson O, Wallin A, Johansson JO, Andreasson U, Andersen O, Haghighi S, Olsson M, Stridsberg M, Svensson J, Blennow K, Zetterberg H (2010)
Converging pathways of chromogranin and amyloid metabolism in the brain
J Alzheimers Dis, 20 (4), 1039-49
PubMed 20413871

Palmqvist S, Minthon L, Wattmo C, Londos E, Hansson O (2010)
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
Alzheimers Res Ther, 2 (5), 29
PubMed 20950460

Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H (2010)
Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
Mol Neurodegener, 5, 2
PubMed 20145736

Stomrud E, Björkqvist M, Janciauskiene S, Minthon L, Hansson O (2010)
Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
Alzheimers Res Ther, 2 (3), 20
PubMed 20576109

Stomrud E, Hansson O, Minthon L, Blennow K, Rosén I, Londos E (2010)
Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years
Neurobiol Aging, 31 (2), 215-23
PubMed 18462837

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010)
Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults
Arch Neurol, 67 (2), 217-23
PubMed 20142530

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L (2010)
Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls
J Alzheimers Dis, 21 (2), 471-8
PubMed 20555147

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L (2010)
Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls
J Alzheimers Dis, 22 (4), 1223-30
PubMed 20930303

Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E (2010)
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Int J Geriatr Psychiatry, 25 (4), 403-10
PubMed 19650161

Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K (2010)
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Brain Res, 1362, 13-22
PubMed 20875798

Zetterberg H, Tullhög K, Hansson O, Minthon L, Londos E, Blennow K (2010)
Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients
Eur Neurol, 63 (6), 326-30
PubMed 20516693

Publications 2009

Boström F, Hansson O, Blennow K, Gerhardsson L, Lundh T, Minthon L, Zetterberg H, Londos E (2009)
Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies
Dement Geriatr Cogn Disord, 28 (4), 314-9
PubMed 19844105

Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O (2009)
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease
PLoS One, 4 (7), e6294
PubMed 19609443

Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Björkqvist M, Träskman-Bendz L, Brundin L (2009)
Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity
Biol Psychiatry, 66 (3), 287-92
PubMed 19268915

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A et al. (2009)
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
JAMA, 302 (4), 385-93
PubMed 19622817

Palmqvist S, Hansson O, Minthon L, Londos E (2009)
Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests
Int J Geriatr Psychiatry, 24 (12), 1405-12
PubMed 19347836

Publications 2008

Boström F, Hansson O, Gerhardsson L, Lundh T, Minthon L, Stomrud E, Zetterberg H, Londos E (2008)
CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies
Neurobiol Aging, 30 (8), 1265-71
PubMed 18191875

Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson O (2008)
Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease
Neurosci Lett, 450 (1), 56-9
PubMed 18996438

Buchhave P, Stomrud E, Warkentin S, Blennow K, Minthon L, Hansson O (2008)
Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease
Dement Geriatr Cogn Disord, 25 (6), 544-52
PubMed 18535375

Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O (2008)
Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment
Neurobiol Aging, 31 (11), 1877-84
PubMed 19070941

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2008)
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
Neurobiol Aging, 31 (3), 357-67
PubMed 18486992

Hedman J, Albinsson L, Ansell C, Tapper H, Hansson O, Holgersson S, Ansell R (2008)
A fast analysis system for forensic DNA reference samples
Forensic Sci Int Genet, 2 (3), 184-9
PubMed 19083819

Palmqvist S, Hansson O, Minthon L, Londos E (2008)
The usefulness of cube copying for evaluating treatment of Alzheimer's disease
Am J Alzheimers Dis Other Demen, 23 (5), 439-46
PubMed 18955723

Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L (2008)
Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting
Dement Geriatr Cogn Disord, 26 (3), 203-11
PubMed 18769065

Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008)
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
Arch Neurol, 65 (8), 1102-7
PubMed 18695061

Publications 2007

Andersson ME, Sjölander A, Andreasen N, Minthon L, Hansson O, Bogdanovic N, Jern C, Jood K, Wallin A, Blennow K, Zetterberg H (2007)
Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
Int J Mol Med, 20 (2), 233-9
PubMed 17611642

Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S (2007)
Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease
Neurobiol Aging, 30 (2), 165-73
PubMed 17646035

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007)
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment
Dement Geriatr Cogn Disord, 23 (5), 316-20
PubMed 17374949

Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, Waldemar G, Minthon L, Blennow K (2007)
Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment
Arch Neurol, 64 (3), 366-70
PubMed 17353378

Stomrud E, Hansson O, Blennow K, Minthon L, Londos E (2007)
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly
Dement Geriatr Cogn Disord, 24 (2), 118-24
PubMed 17622715

Publications 2006

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Lancet Neurol, 5 (3), 228-34
PubMed 16488378

Publications 2003

Hansson O, Nylandsted J, Castilho RF, Leist M, Jäättelä M, Brundin P (2003)
Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression
Brain Res, 970 (1-2), 47-57
PubMed 12706247

Maciel EN, Kaminski Schierle GS, Hansson O, Brundin P, Castilho RF (2003)
Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents
Exp Neurol, 183 (2), 430-7
PubMed 14552883

Olsson T, Hansson O, Nylandsted J, Jäättelä M, Smith ML, Wieloch T (2003)
Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia
Exp Brain Res, 154 (4), 442-9
PubMed 14579003

Publications 2002

Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002)
Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease
Neuron, 33 (6), 849-60
PubMed 11906693

Publications 2000

Brundin P, Karlsson J, Emgård M, Kaminski Schierle GS, Hansson O, Petersén Å, Castilho RF (2000)
Improving the Survival of Grafted Dopaminergic Neurons: A Review Over Current Approaches
Cell Transplant, 9 (2), 179-195
PubMed 28153062